Welcome to The Intel, the Visiopharm Newsletter that brings you our latest news and digital pathology content each month. Here are the highlights of this month:
See you at the European Congress of Pathology in Florence!
As always, feel free to get in touch if you have any questions or would like to book a demo. You can also check out our Resources page for the latest guides, posters and webinars.
Visiopharm and UMC Utrecht achieve breakthrough in AI-powered detection of breast cancer lymph node metastases
Photo by Ivar Pel
The Pathology Department at the University Medical Center Utrecht (UMC Utrecht) in the Netherlands has successfully validated Visiopharm's AI application in their CONFIDENT-B trial.
Key Highlights:
100% Sensitivity: Our AI achieved a remarkable sensitivity for detecting clinically relevant metastases.
AI-assisted pathologists spent 39% less time on their assessments compared to reviews without the AI.
The UMC Utrecht team's study, demonstrating the exceptional performance of Visiopharm's AI app, has been accepted for publication in the prestigious journal, Nature Cancer.
Prof. Paul Van Diest, Head of the pathology department at UMC Utrecht, expressed his enthusiasm:
“The integration of AI technology into our pathology workflow represents a significant advancement in our diagnostic capabilities. The high sensitivity achieved, along with the substantial cost savings and workflow improvements, underscore the potential of AI in transforming cancer diagnostics. We are currently validating Visiopharm’s AI applications for other indications and the initial results are promising.”
New spatial neighborhood analysis tools in Phenoplex™
We are excited to introduce the new spatial neighbourhood analysis tools in Phenoplex, the latest iteration of our complete workflow for all your multiplex image analysis needs!
Dr. Fabian Schneider, our Research Product Manager, provides a quick overview of these exciting new features in the video below.
If you are interested in a demo of the new feature, contact us here.
CUSTOMER SPOTLIGHT
Straticyte™ – A digitally delivered oral cancer predictor – powered by Visiopharm analysis
We sat down with Dr. Ken Pritzker, co-founder of Proteocyte AI, to delve into their innovative prognostic LTD test, Straticyte™. This digitally delivered oral cancer predictor, powered by Visiopharm analysis, represents a significant leap forward in early cancer detection and patient care.
Straticyte can calculate the 5-year probability that dysplastic lesions will progress to cancer.
"The test is so good that if the Straticyte value is low, the patient can go back to live a normal life. But for cases with an elevated Straticyte value, those patients need to be watched closely and followed up against a possible recurrence or cancer. So compared to the current practice, Straticyte provides greater objectivity, sensitivity, and predictive power." - Dr. Pritzker.
